Abstract
The aim of this study was to evaluate the efficacy of the PRP in a cohort of COPD patients according to currently GOLD classification.
METHODS: Prospective study performed in COPD patients included in a PRP of a tertiary center. Clinical data (pre and post PRP) was collected. Patients were classified using the GOLD 2011 guidelines. Efficacy was evaluated in terms of: improvement in 6MWT distance (≥35m), dyspnea (≥1 mMRC), and quality of life (SF12, SGRQ, London).
RESULTS: 97 of 110 patients completed the PRP (64±6yrs, 90% male, FEV1 40±16%, baseline dyspnea of 3(2-3)). An improvement in dyspnea (3[2-3] vs 2[1-2], P=0.01) and exercise tolerance (344±83m vs 392±80m, P<0.001) were observed. The time until first exacerbation was 11.2±10.3months and a significant improvement in quality of life were found. The distribution according to GOLD groups is described in Table 1.
Patients in group C had an increased walking distance after PRP compared to group D and B. However, the major reduction in dyspnea degree was achieved in groups B and D (≥1 mMRC). No significant difference among groups in improvement of quality of life was observed.
CONCLUSIONS: The improvement in different outcomes after PRP could depend on GOLD groups. Patients in group C were who most increased the distance in 6MWT meanwhile patients in group B only improved the dyspnea after PRP.
Funded by SEPAR and FUCAP.
- © 2014 ERS
